Monthly changes in serum levels of S100B protein as a predictor of metastasis development in high‐risk melanoma patients
- 22 January 2020
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (7) , 1482-1488
Abstract
Background: The role of S100B protein in detecting early melanoma relapses is controversial, since most metastasis occur within normal values of S100B.Objective: The aim of this study was to assess the performance of S100B in detecting early disease progression in high‐risk melanoma patients.Methods: Retrospective cohort study including patients with an initial diagnosis of stage IIB, IIC and III melanoma between January 2003 and July 2013. All patients were followed up in accordance with an intensive protocol based on imaging studies and serum S100B levels every 3–6 months. We compared two methods to evaluate changes in S100B. The classic method referring to a single determination of S100B above the cut‐off level at the time of metastasis, which was evaluated in all patients. And a new method based on monthly changes of S100, which was used in the setting of patients with S100B levels within the normal range.Results: Overall, 289 of patients were followed up for 44 months (IQR 17–73) and 45% developed metastases. During the study period, 129 patients relapsed of which 46 (35.7%) present elevated values of S100B at the time of relapse. The classic method had a sensitivity and specificity of S100B protein of 35.7% and 92.5%, respectively. Furthermore, for the patients that relapsed with normal values of S100B, the new method was applied and showed a sensitivity and specificity of 41.1% and 92.4%, respectively, allowing to detect additional relapses that were missing by the classic method.Conclusion: During follow‐up of high‐risk melanoma patients, rising serum S100B values within the normal range can be an important clue to disease progression.Keywords
This publication has 33 references indexed in Scilit:
- Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015Journal of the European Academy of Dermatology and Venereology, 2013
- Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2013
- Review of Diagnostic Imaging Modalities for the Surveillance of Melanoma PatientsDermatology Research and Practice, 2011
- Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanomaBMC Cancer, 2011
- Prognostic value of serial blood S100B determinations in stage IIB–III melanoma patients: A corollary study to EORTC trial 18952European Journal of Cancer, 2011
- S100B's double life: Intracellular regulator and extracellular signalBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694Journal of Clinical Oncology, 2009
- Likelihood ratios: Clinical application in day-to-day practiceIndian Journal Of Ophthalmology, 2009
- Risk of Epithelial Ovarian Cancer Recurrence in Patients With Rising Serum CA-125 Levels Within the Normal RangeJournal of Clinical Oncology, 2005
- S-100 protein in peripheral blood: A marker for melanoma metastasesJournal of the American Academy of Dermatology, 1999